EPO and perinatal asphyxia: Based on these findings, a Phase III multicentred High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) study, by Wu, Juul and colleagues [130] (Table 4) is recruiting 500 newborns ≥36 weeks-of-age with moderate/severe HIE.